Literature DB >> 19450754

Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

Hirohisa Nakamae1, Katharine A Kirby, Brenda M Sandmaier, Lalita Norasetthada, David G Maloney, Michael B Maris, Chris Davis, Lawrence Corey, Rainer Storb, Michael Boeckh.   

Abstract

Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell chimerism for up to half a year with prolonged presence of host T cell immunity. In this study, we examined whether this translates into differences in the risks and/or severity of cytomegalovirus (CMV) infection and disease. We analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489 myeloablative hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive recipients, no difference in the overall hazards of CMV infection at any level (adjusted hazard ratio [adj. HR] 0.9, 95% confidence interval [95% CI]: 0.7-1.0, P = .14) was noted; however, NM-HCT was associated with a lower risk of high-grade CMV infection (adj. HR 0.7, 95% CI: 0.5-0.9, P = .02). CMV disease rates were similar between the groups during the first 100 days after HCT, but NM-HCT recipients had an increased risk of late CMV disease (adj. HR 2.0, 95% CI 1.2-3.4). The increased risk of late CMV disease after NM-HCT was pronounced during the earlier years of the study period, but not detectable in more recent years. Contrary to earlier reports, survival following CMV disease was not reduced after NM-HCT when compared to M-HCT recipients. These results suggest that residual host cells after NM-HCT reduce progression to higher CMV viral load in NM-HCT recipients; however, this effect does not appear to protect against serious complications of CMV. Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in M-HCT recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450754      PMCID: PMC2763357          DOI: 10.1016/j.bbmt.2009.02.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

1.  Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Authors:  Mary K Wloch; Larry R Smith; Souphaphone Boutsaboualoy; Luane Reyes; Christina Han; Jackie Kehler; Heather D Smith; Linda Selk; Ryotaro Nakamura; Janice M Brown; Thomas Marbury; Anna Wald; Alain Rolland; David Kaslow; Thomas Evans; Michael Boeckh
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

2.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Authors:  H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

Review 3.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

4.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 5.  Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

Authors:  L Feinstein; B Sandmaier; D Maloney; P A McSweeney; M Maris; C Flowers; J Radich; M T Little; R A Nash; T Chauncey; A Woolfrey; G Georges; H P Kiem; J M Zaucha; K G Blume; J Shizuru; D Niederwieser; R Storb
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

6.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

Authors:  Hermann Einsele; Eddy Roosnek; Nathalie Rufer; Christian Sinzger; Susanne Riegler; Jürgen Löffler; Ulrich Grigoleit; Arnaud Moris; Hans-Georg Rammensee; Lothar Kanz; Annette Kleihauer; Friederike Frank; Gerhard Jahn; Holger Hebart
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.

Authors:  Christian Junghanss; Michael Boeckh; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Thomas Chauncey; Peter A McSweeney; Marie-Térèse Little; Lawrence Corey; Rainer Storb
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

Authors:  Dietger Niederwieser; Michael Maris; Judith A Shizuru; Effie Petersdorf; Ute Hegenbart; Brenda M Sandmaier; David G Maloney; Barry Storer; Thoralf Lange; Thomas Chauncey; Michael Deininger; Wolfram Pönisch; Claudio Anasetti; Ann Woolfrey; Marie-Terese Little; Karl G Blume; Peter A McSweeney; Rainer F Storb
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

10.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

Authors:  Michael B Maris; Dietger Niederwieser; Brenda M Sandmaier; Barry Storer; Monic Stuart; David Maloney; Effie Petersdorf; Peter McSweeney; Michael Pulsipher; Ann Woolfrey; Thomas Chauncey; Ed Agura; Shelly Heimfeld; John Slattery; Ute Hegenbart; Claudio Anasetti; Karl Blume; Rainer Storb
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  36 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.

Authors:  Joanna M Schaenman; Sumana Shashidhar; Chanu Rhee; Jonathan Wong; Shelly Navato; Ruby M Wong; Dora Y Ho; Sally Arai; Laura Johnston; Janice M Brown
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

3.  Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time.

Authors:  Celalettin Ustun; Jiří Slabý; Ryan M Shanley; Jan Vydra; Angela R Smith; John E Wagner; Daniel J Weisdorf; Jo-Anne H Young
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-21       Impact factor: 5.742

4.  Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.

Authors:  Hirohisa Nakamae; Barry Storer; Brenda M Sandmaier; David G Maloney; Chris Davis; Lawrence Corey; Rainer Storb; Michael Boeckh
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 5.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

6.  Bacterial foodborne infections after hematopoietic cell transplantation.

Authors:  Nicole M Boyle; Sara Podczervinski; Kim Jordan; Zach Stednick; Susan Butler-Wu; Kerry McMillen; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-12       Impact factor: 5.742

7.  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients.

Authors:  Filippo Milano; Steven A Pergam; Hu Xie; Wendy M Leisenring; Jonathan A Gutman; Ivy Riffkin; Victor Chow; Michael J Boeckh; Colleen Delaney
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 8.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

9.  Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

Authors:  Suzanne M McGoldrick; Marie E Bleakley; Abraham Guerrero; Cameron J Turtle; Tori N Yamamoto; Shalini E Pereira; Colleen S Delaney; Stanley R Riddell
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

10.  The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.

Authors:  Giovanna Travi; Steven A Pergam; Hu Xie; Paul Carpenter; Hans-Peter Kiem; Lawrence Corey; Michael J Boeckh
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.